Home › Pharmacology › Antibiotics Inhibiting Protein Synthesis

Antibiotics Inhibiting Protein Synthesis

For medical students2 min readUpdated 2026-10-10

Antibiotics in this group halt bacterial reproduction by interfering with translation—the assembly of protein molecules. These drugs bind to various sites on the bacterial ribosome, blocking genetic code reading, amino acid attachment, or translocation along messenger RNA.

Main TargetBacterial ribosome (small 30S and large 50S subunits)

Reading DirectionInformation is read from mRNA strictly in the 5' to 3' direction

Major GroupsMacrolides, tetracyclines, aminoglycosides, chloramphenicol, lincosamides

Stop SignalStop codons UAA, UAG, or UGA in the A-site trigger termination

Structure of the Bacterial Translation Apparatus

To understand the sites of action of protein synthesis inhibitors in detail, it is essential to clearly picture the structural components of the bacterial translational apparatus. The bacterial ribosome consists of two parts: the small (30S subunit) and the large (50S subunit).

Within this complex, two major functional centers host the primary reactions:

A-site (aminoacyl site): A "landing zone" and entry point for new transfer RNA (tRNA) carrying the next amino acid for the growing protein.
P-site (peptidyl site): The site where the growing peptide chain is securely held.

Protein assembly itself proceeds based on information encoded in messenger RNA (mRNA). The ribosome reads this genetic material in a strictly unidirectional manner: from the 5' end to the 3' end.

Action on the Small 30S Subunit

The first group of drugs interferes with translation during the early stages of mRNA interaction with the small ribosomal subunit.

Aminoglycosides target the 30S subunit. By binding to it, they cause a spatial distortion of the ribosomal structure. The primary consequence is miskreading of the mRNA code. The ribosome makes errors, incorporating completely incorrect amino acids into the synthesized chain, ultimately producing defective proteins unable to perform their functions.
Tetracyclines block the elongation phase. Their site of action is the A-site on the 30S subunit. These drugs heavily block tRNA binding to this center. Consequently, the incoming tRNA carrying the required amino acid physically cannot attach to the ribosomal complex, completely halting further elongation of the peptide chain.

Action on the Large 50S Subunit

The second group of antibiotics affects enzymatic processes and mechanical ribosomal movement by binding to the large 50S subunit.

Chloramphenicol inhibits the transpeptidation phase. It acts on the enzymatic center of the 50S subunit, blocking peptidyl transferase. This prevents the transfer of the growing peptide chain from the tRNA in the P-site to the new amino acid in the A-site. Peptide bond formation is halted.
Macrolides inhibit the translocation phase. Normally, the ribosome must shift along the mRNA by exactly one triplet (codon). Macrolides, by binding to the 50S subunit, block this movement. As a result, the A-site is not cleared to receive the next tRNA, and the "empty" spent tRNA cannot leave the P-site, making further protein synthesis impossible.

Physiology of Translation Termination

Physiologically, elongation is a strict sequence of repeating cycles. Key steps of each cycle include binding of aminoacyl-tRNA to the A-site, peptide bond formation, and finally, translocation. Translocation involves moving the growing peptide, which gradually exits through a special exit tunnel in the ribosome.

The completion of protein synthesis is called termination. This step occurs when a stop codon (UAA, UAG, or UGA) enters the A-site. Specialized proteins—release factors—recognize this stop codon and activate terminal processes. Termination results in the release of the fully synthesized protein molecule and dissociation of the ribosome-mRNA complex.

Mnemonic

To quickly remember the sites of action, use the rule: Aminoglycosides and Tetracyclines bind to the small 30S subunit. Macrolides and cHloramphenicol attack the large 50S subunit.

Frequently asked questions

Which classes of antibiotics bind to the large 50S ribosomal subunit?

The following protein synthesis inhibitors bind to the large 50S bacterial ribosomal subunit:

Macrolides: Localized to the 50S subunit; mechanism: inhibition of translocation.
Ketolides: Act on the 50S subunit; telithromycin has a higher affinity for the 50S subunit and binds to an additional site on 23S rRNA.
Lincosamides: Target the 50S ribosomal subunit; inhibit protein synthesis at the translocation step / block peptide bond formation.
Chloramphenicol: Localized to the 50S subunit; causes blockade of peptidyl transferase.
Linezolid: Binds to the P-site of the 50S ribosomal subunit and blocks initiation complex formation.
Quinupristin/dalfopristin: Target the 50S ribosomal subunit; block peptidyl transferase, disrupt translocation, and inhibit the exit of the elongating peptide chain from the ribosome.

What is the mechanism of action of lincosamides?

The mechanism of lincosamides involves the inhibition of intracellular protein synthesis during the translocation phase. Their target is the 50S subunit of the bacterial ribosome. By binding to it, lincosamides block peptide bond formation, halting peptide chain elongation. Their site of action is similar to macrolides, which creates competitive antagonism for ribosomal binding when used together.

Which protein synthesis inhibitors are bactericidal?

Among protein synthesis inhibitors, only a few groups are bactericidal.

Aminoglycosides: An exception among protein synthesis inhibitors, providing irreversible inhibition and a bactericidal effect.
Combination drugs (quinupristin/dalfopristin): Act bactericidally against most Gram-positive bacteria.
Lincosamides: Primarily bacteriostatic, though they may exhibit bactericidal effects at high concentrations.

What are the mechanisms of bacterial resistance to macrolides?

There are four primary mechanisms of bacterial resistance to macrolides:

Enzymatic inactivation: Production of esterases that hydrolyze macrolides; characteristic of enterococci.
Target modification: Alteration of the ribosomal binding site via chromosomal mutations or methylation; methylases modify the macrolide binding site on the ribosome.
Impaired transport: Reduced cell membrane permeability or active efflux of the drug from the cell.
Cross-resistance (MLS phenotype): Constitutive methylase production confers resistance to macrolides, lincosamides, and group B streptogramins.

At what stage of protein synthesis do tetracyclines act?

They block the elongation phase. The drug binds to the A-site of the small 30S subunit and prevents the attachment of new transfer RNA.

What is the result of aminoglycosides binding to the ribosome?

They distort the conformation of the 30S subunit. This causes misreading of messenger RNA, leading the bacterium to synthesize defective proteins with incorrect amino acids.

What is the core mechanism of action of macrolides?

Macrolides inhibit translocation—the movement of the ribosome along mRNA. Consequently, the A-site remains occupied, and the next amino acid cannot enter the cycle.

Which antibiotic blocks peptidyl transferase?

Chloramphenicol. It binds to the enzymatic center of the 50S subunit and halts the transpeptidation reaction (peptide bond formation).

Go deeper

Mechanism of action of lincosamides on the bacterial cell
Role of release factors in translation termination
Features of growing peptide exit through the ribosomal tunnel
Cyclical nature of the elongation phase in bacterial protein synthesis